

HBM Healthcare Investments Ltd aims for long-term capital appreciation by investing in private and public companies within the Healthcare sector worldwide

### Net Performance Figures (CHF)


	Share	NAV
YTD	+48.0%	+33.0%
2018	+21.8%	+9.9%
2017	+40.5%	+25.8%
2016	+2.5%	-7.2%
5Y Return p.a.	+21.0%	+12.8%
10Y Return p.a.	+18.3%	+14.4%
Distribution yield		
2019	4.4%	
2018	4.9%	
2017	5.2%	

### Facts & Figures (CHF)


Total Assets	1'784 million
Net Assets (NAV)	1'532 million
Market Capitalisation	1'549 million
Share price	222.50
NAV per share	220.17
Premium	1.1%
LTM average daily liquidity	6'347 shares ~ 1.4 million
Number of issued shares	6.96 million
Number of shareholders	2'338
ISIN	CH0012627250
Bloomberg Ticker	HBMN SW Equity

### Portfolio Breakdown


#### Asset Allocation




#### Currency Allocation



#### Development Phase



#### Therapeutic Area



### About Us

- ▶ Founded in 2001 and listed on SIX Exchange since 2008
- ▶ Successful track record of exits validated by more than 60 trade sales and IPOs since 2001
- ▶ Broadly diversified portfolio of 30-45 core holdings
- ▶ International and stable shareholder base with high insider ownership percentage
- ▶ Attractive dividend yield of 3-5% per annum

### Performance over 5 Years (CHF)



### Investment Strategy













#### Objective

- ▶ Aims for long-term capital appreciation by investing in private and public healthcare companies worldwide
- ▶ Maintain a diversified portfolio – major focus on companies with products on market or at an advanced stage of development (near cash-flow-positive and/or phase II drug data)

#### Investment Approach

- ▶ Fundamental long with private and public positions
- ▶ Bottom-up selection of companies with solid long-term growth potential
- ▶ Active lead/co-lead investor in private companies with board representation
- ▶ Maximum single position limit at time of investment up to 10% of NAV

## Largest Investments

Company	Core business	Phase of Lead Product	Ticker	Market Capitalisation (CHF m)	Ownership in %	Book Value (CHF m)	in % of Total Assets
 CATHAY INDUSTRIAL BIOTECH	Long chain diacids, carbohydrates and special enzymes	Market	Private	2'693*	7.9	205.5	11.5
 mAbs	Developing novel antibody therapeutics for oncology targets	Phase III	YMAB (ex private)	1'200	7.0	84.2	4.7
 SpringWorks THERAPEUTICS	Targeted oncology treatment	Phase III	SWTX (ex private)	1'599	2.9	47.0	2.6
 argenx	Drugs for autoimmune and cancer diseases	Phase II	ARGX	6'670	0.8	44.5	2.6
 VIELABIO	Late-stage drug for treatment of severe inflammation and autoimmune diseases	Phase III	VIE (ex private)	1'339	3.4	45.9	2.6
 PACIRA PHARMACEUTICALS, INC.	Injectable medicines with (patented) controlled release of active drug	Market	PCRX (ex private)	1'825	2.3	41.6	2.3
 NEURELIS	Specialty pharma company developing a treatment for epileptic seizures	Phase III	Private	246*	15.2	37.4	2.1
 Zogenix	Therapeutic solutions for CNS disorders and rare diseases	Phase III	ZGNX	2'223	1.4	39.9	1.7
 XBioTech	Drug for severe skin diseases	Phase III	XBIT	741	4.1	30.6	1.7
 IMMUNOMEDICS, INC.	Drugs for cancer diseases	Phase II	IMMU	4'260	0.7	30.2	1.7
 Turning Point Therapeutics	Drugs for the treatment of severe cancers	Phase II	TPTX (ex private)	2'166	1.4	30.1	1.7
 biohaven pharmaceuticals	Targeting neurological diseases	Phase III	BHVN	3'003	1.0	29.1	1.7

\* Implied company valuation

## Latest Private Investments



Proprietary technology platform with drugs in clinical stage for autoimmune diseases



Late-stage clinical asset for treatment of severe inflammation and autoimmune diseases



Clinical-stage company developing immunotherapies focused on multiple difficult-to-treat oncology indications



Synthesis of complex pharmaceutical compounds with USD 60 million in revenues, profitable



Antibodies for the treatment of rare pediatric oncology indications, incl radiolabelled and bispecific mAbs



Late-stage clinical asset for the treatment of narcolepsy (with and without cataplexy)

## Contact Details

### HBM Healthcare Investments Ltd

Bundesplatz 1  
6301 Zug / Switzerland  
Phone + 41 41 710 75 77  
Fax + 41 41 710 75 78  
investor.relations@hbmhealthcare.com  
www.hbmhealthcare.com

#### Disclaimer

This document is intended to be for information purposes only and should not be construed as an offer or solicitation for the purchase of this fund. HBM has expressed its own views in this document and these may change. Past performance is not a reliable indicator of future results, prices of shares and the income from them may fall as well as rise and investors may not get back the amount originally invested. Some information quoted was obtained from external sources HBM considers to be reliable. No responsibility can be accepted for errors of fact obtained from third parties, and this data may change with market conditions.